Physician profile
Robin Trumbull
NPI 1568553030
$2,058.38
in general payments reported to CMS, 2019-2025
22 companies · $81.30 in 2025
The $81.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $99.26 · 2021: $202 · 2022: $626 · 2023: $500 · 2024: $39.04 · 2025: $81.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $434.83 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $192.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $184.59 | 2019-2020 | |
| Novo Nordisk INC | $159.23 | 2021-2024 | Ozempic, Rybelsus |
| Avanir Pharmaceuticals, INC. | $140.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $133.83 | 2022-2023 | Rexulti |
| Abbott Laboratories | $124.96 | 2022 | |
| Abbvie INC. | $110.04 | 2020-2023 | Vraylar |
| Ironshore Pharmaceuticals INC. | $103.16 | 2022 | |
| Nestle Healthcare Nutrition INC. | $80.27 | 2023 | |
| Novartis Pharmaceuticals Corporation | $64.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.61 | 2021 | |
| Allergan, INC. | $47.66 | 2019-2020 | |
| Mylan Specialty L.P. | $40.17 | 2022-2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $37.47 | 2025 | Breztri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.35 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $28.47 | 2022 | |
| Corcept Therapeutics | $27.75 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $19.88 | 2021 | |
| Lilly USA, LLC | $17.07 | 2020 | |
| Acorda Therapeutics, INC | $15.88 | 2023 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $13.09 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Trumbull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.